Veoza TM
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional.
Active ingredients: fezolinetant
Brand name
(ARTG)
: VEOZA fezolinetant 45 mg film coated tablet blister packDownload the Consumer Medicine Information Leaflet
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
What this medicine is used for
(ARTG)
VEOZA is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause (see section 5.1 Pharmacodynamic Properties Clinical Trials)
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Tablet, film coated
- Oral
- Fezolinetant 45 mg tablets are round, light red, film coated tablets debossed with the Astellas logo and 645 on the same side
Storage conditions
(ARTG)
- Store below 30 degrees Celsius
- Shelf lifetime is 36 Months.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is
- 10 tablets (starter pack) pack
- 100 tablets pack
- 30 tablets pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient fezolinetant
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
